Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Tuesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Zentalis Pharmaceuticals to post earnings of ($0.70) per share for the quarter.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. On average, analysts expect Zentalis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL traded up $0.03 during trading hours on Thursday, hitting $1.45. 696,943 shares of the stock were exchanged, compared to its average volume of 1,545,558. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $13.24. The business has a 50-day moving average of $1.59 and a 200-day moving average of $2.46. The firm has a market capitalization of $104.13 million, a P/E ratio of -0.58 and a beta of 1.80.

Insider Activity at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were acquired at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now owns 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ingmar Bruns bought 20,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, February 6th. The stock was purchased at an average price of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 101,000 shares of company stock valued at $178,200 over the last 90 days. Insiders own 3.60% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on ZNTL shares. UBS Group lowered their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 27th. Wedbush reaffirmed a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th. Finally, Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.